GSK3B and autoimmune thrombocytopenic purpura: These findings provide a substantial body of evidence for a novel therapeutic strategy in ITP, that the inhibition of GSK‐3β could modulate the polarization and function of macrophages in ITP, and provide a novel irreversible covalent GSK‐3βi as a potential medicine for ITP.